Genetic and environmental aspect of polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 26, Issue 11, 2003, Pages 1151-1159

  Carmina, Enrico ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Hyperandrogenism; Insulin resistance; Obesity; PCOS

Indexed keywords

CALPAIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

BODY WEIGHT; CULTURAL FACTOR; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; FOOD QUALITY; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC REGULATION; HEREDITY; HOMOZYGOSITY; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; REVIEW; SOCIOECONOMICS; STEROIDOGENESIS;

EID: 1042269516     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345266     Document Type: Review

References (83)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29: 181-91.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333: 853-61.
3. Legro RS. Polycystic ovary syndrome: the new millennium. Mol Cell Endocrinol 2001, 184: 87-93.
4. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000, 132: 989-93.
5. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome: a form of functional ovarian hyperandrogenism due to a dysregulation of androgen secretion. Endocr Rev 1995, 16: 322-53.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774-800.
7. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002, 78: 569-76.
8. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002, 13: 251-7.
9. Shoupe E, Lobo RA. The influence of androgens on insulin resistance. Fertil Steril 1984, 41: 385-8.
10. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81: 952-60.
11. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986, 62: 904-10.
12. Nestler JE, Jakubowicz DJ, de Vargas AF, Brick C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998, 83: 2001-5.
13. Lobo RA, Carmina E. Polycystic ovary syndrome. In: Lobo RA, Mishell DR Jr, Paulson RJ, Shoupe D eds. Mishell's Textbook of Infertility, Contraception and Reproductive Endocrinology. 4th ed. Boston: Blackwell. 1997, 363-83.
14. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990, 70: 699-704.
15. Vidal-Puig A, Munoz-Torres M, Garcia-Calvente C, et al. Reduction of endogenous ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. J Endocrinol Invest 1994, 17: 647-52.
16. Glass AR. Endocrine aspects of obesity. Med Clin North Am 1989, 73: 139-60.
17. Carmina E. Antiandrogens for the treatment of hirsutism. Exper Opin Invest Drugs 2002, 11: 357-63.
18. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo controlled trial. J Clin Endocrinol Metab 2001, 86: 1626-32.
19. Abbott DH, Dumesic DA, Eisner JR, et al. The prenatally androgenized female rhesus monkey as a model for PCOS. In: Azziz R, Nestler JE, Dewailly D eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven. 1977, 369-82.
20. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002, 174: 1-5.
21. Givens JR. Familial polycystic ovarian disease. Endocrinol Metab Clin North Am 1988, 17: 1-17.
22. Hague WM, Adams J, Feeders ST, Peto TEA, Jacobs HS. Familial polycystic ovaries: a genetic disease. Clin Endocrinol (Oxf) 1988, 38: 65-9.
23. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993, 38: 653-9.
24. Cooper HE, Spellacy WN, Prem KA, Cohen WD. Hereditary factors in Stein-Leventhal syndrome. Am J Obstet Gynecol 1968, 100: 371-87.
25. Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal inherent trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999, 84: 38-43.
26. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001, 7: 405-10.
27. Lund O, Magnus P, Sandvik L, Hoglo S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest 1989, 28: 23-30.
28. Azziz R, Kahsar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000, 13 (Suppl 5): 1303-6.
29. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001, 75: 53-8.
30. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenism rather than menstrual irregularities. J Clin Endocrinol Metab 2002, 87: 2128-33.
31. Jahanfar S, Eden JZ, Warren P, Seppala M, Jagger H. A twin study of polycystic ovary syndrome. Fertil Steril 1995, 61: 478-86.
32. Carmina E, Lobo RA. Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome. J Endocrinol Invest 1998, 21: 580-8.
33. Franks S, Gilling-Smith C, Gharani N, McCarthy M. Pathogenesis of polycystic ovary syndrome: evidence for a genetically determined disorder of ovarian androgen production. Hum Fertil (Camb) 2001, 3: 77-9.
34. Strauss JF 3rd, Wood JR, Christenson LK, Mc Allister JM. Strategies to elucidate the mechanism of excessive theca cell androgen production in PCOS. Mol Cell Endocrinol 2002, 186: 183-8.
35. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated cells from polycystic ovaries. J Clin Endocrinol Metab 1994, 79: 1158-65.
36. Nelson VL, Legro RS, Strauss JF, Mc Allister JM. Augmented androgen production is a stable phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999, 13: 946-57.
37. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF, Mc Allister JM. Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2001, 85: 2304-11.
38. Nelson VL, Qin K, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86: 5925-33.
39. San Millan JL, Sancho J, Calvo RM, Escobar-Morreale HF. Role of the pentanucleotide (tttta) (n) polymorphism in the promoter of the gene CYP11α gene in the pathogenesis of hirsutism. Fertil Steril 2001, 75: 797-802.
40. Wood JR, Nelson VL, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS). Theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003, 278: 26380-90.
41. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 161-5.
42. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest 2002, 109: 973-81.
43. Dunaif A, Xia J, Book C, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96: 801-10.
44. Ciaraldi TP. Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. J Pediatr Endocrinol Metab 2000, 13 (Suppl 5): 1291-3.
45. Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulator polymorphism with polycystic ovary syndrome. Lancet 1997, 349: 986-90.
46. Bennett ST, Todd JA, Waterworth DM, Franks S, McCarthy MI. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Lancet 1997, 349: 1771-2.
47. Huxtable SJ, Saker PJ, Haddad L, et al. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type II diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 2000, 49: 126-30.
48. Vankova M, Vrbikova J, Hill M, Cinek O, Bendlova B. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Ann NY Acad Sci 2002, 967: 558-65.
49. Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002, 78: 1240-3.
50. El Mkadem SA, Lautier C, Macari F, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate to severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001, 50: 2164-8.
51. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 4297-300.
52. Peral B, San Millan JL, Castello R, Moghetti P, Escobar-Morreale HF. The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002, 87: 3977-83.
53. Korhonen S, Romppanen EL, Hiltunen M, et al. Lack of association between C-850T polymorphism of the gene encoding tumor necrosis factor-alpha and polycystic ovary syndrome. Gynecol Endocrinol 2002, 16: 271-4.
54. Carafoli E, Molinari M. Calpain: a protease in search of function? Biochem Biophys Res Commun 1998, 18: 193-203.
55. Cox NJ, Frigge M, Nicolae DL, et al. Loci on chromosome 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet 1999, 21: 213-5.
56. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type II diabetes mellitus. Nat Genet 2000, 26: 163-75.
57. Rasmussen SK, Unhammer SA, Berglund L, et al. Variants within the calpain-10 gene an chromosome 2q37 (NID-DM1) and relationship to type 2 diabetes, insulin resistance and impaired acute insulin secretion among Scandinavian Caucasians. Diabetes 2002, 51: 3561-7.
58. Orho-Melander M, Klannemark M, Svensson MK, Ridderstrale M, Lindgren CM, Groop L. Variants of calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 2002, 51: 2658-64.
59. Ehrmann D, Schwarz PE, Hara M, et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 1669-73.
60. Gonzalez A, Abril E, Roca A, et al. CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 3971-6.
61. Haddad L, Evans JC, Gharani N, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2002, 87: 2606-10.
62. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65: 261-311.
63. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002, 18 (Suppl 2): S10-5.
64. McIntyre FA, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin Endocrinol (Oxf) 2002, 57: 303-11.
65. Hara M, Alcoser SY, Qaadir A, Belswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002, 87: 772-5.
66. Orio F Jr, Matarese G, Di Biase S, et al. Exon 6 and 2 polymorphisms of peroxisome proliferators activated receptor γ in women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003 (in press).
67. Stumvoll M, Stefan N, Fritsche A, et al. Interaction effect between common polymorphism in PPARgamma2 (Pro12Ala) and insulin receptor substrate (Gly972Arg) on insulin sensitivity. J Mol Med 2002, 80: 1-2.
68. Savage DB, Agostini M, Barroso I, et al. Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 2002, 31: 379-84.
69. Jacobs HS. Environmental factors in PCOS. In: Azziz R, Nestler JE, Dewailly D eds. Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven. 1997, 339-45.
70. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999, 84: 1897-9.
71. Knochenhauer ES, Key TJ, Kashar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83: 3078-82.
72. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected women from Spain. J Clin Endocrinol Metab 2000, 85: 2434-8.
73. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in Polycystic Ovary Syndrome? Am J Obstet Gynecol 1992, 167: 1807-12.
74. Kauffman RP, Baker VM, Dimarino I, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol 2002, 187: 1362-9.
75. Carmina E, Legro RS, Stamets K, Lowell JE, Lobo RA. Difference in body weight between US and Sicilian women with PCOS: influence of the diet. Hum Reprod 2003, 11: 2289-93.
76. Bougneres P. Genetics of obesity and type 2 diabetes: tracking pathogenetic traits during the predisease period. Diabetes 2002, 51 (Suppl 3): S295-303.
77. Clement K, Boutin P, Froguel P. Genetics of obesity. Am J Pharmacogenomics 2002, 2: 177-87.
78. Steinle NI, Hsueh WC, Snitker S, et al. Eating behavior in the old order Amish: heritability analysis and a genome-wide linkage analysis. Am J Clin Nutr 2002, 75: 1098-106.
79. Taylor AE, Hubbard JL, Anderson EJ, Hall JE. Dietary composition in the pathophysiology of polycystic ovary syndrome: diet composition in normal and PCOS women. Program of the 84th Ann. Meeting of the Endocrine Society, San Francisco. 2002, p. 468 (abstract P2-633).
80. Carmina E, Legro R, Stamets K, Lowell J, Lobo RA. The influence of diet in the obesity and metabolic alterations in polycystic ovary syndrome. Program of the 83rd Annual Meeting of the Endocrine Society, Denver, Colorado, USA, June 20-23, 2001, p. 394 (abstract P2-467).
81. Weiss EP, Brown MD, Shuldiner AR, Hagberg JM. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 2002, 10: 145-57.
82. Luan J, Browne PO, Harding AH, et al. Evidence for the gene-nutrient interaction at the PPARgamma locus. Diabetes 2001, 50: 686-9.
83. Ibanez L, Valls C, Potau N, Marcos MV, De Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birth weight effect. Clin Endocrinol (Oxf) 2001, 55: 667-72.